Codex DNA (DNAY) to Release Earnings on Tuesday

Codex DNA (NASDAQ:DNAYGet Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, May 10th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter. Codex DNA has set its FY 2022 guidance at EPS.

Codex DNA (NASDAQ:DNAYGet Rating) last released its earnings results on Tuesday, March 22nd. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.05). The business had revenue of $3.08 million for the quarter, compared to the consensus estimate of $3.83 million. On average, analysts expect Codex DNA to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ DNAY remained flat at $$4.15 during mid-day trading on Wednesday. 128,978 shares of the company were exchanged, compared to its average volume of 327,032. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.57 and a quick ratio of 9.33. The stock’s 50-day simple moving average is $6.72. Codex DNA has a 1 year low of $3.66 and a 1 year high of $25.70.

DNAY has been the subject of several recent analyst reports. Cowen assumed coverage on shares of Codex DNA in a research note on Wednesday, March 2nd. They issued a “buy” rating for the company. Zacks Investment Research upgraded shares of Codex DNA from a “sell” rating to a “hold” rating in a report on Monday. Finally, KeyCorp reduced their target price on shares of Codex DNA from $30.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, March 28th.

A number of large investors have recently added to or reduced their stakes in DNAY. Millennium Management LLC boosted its position in shares of Codex DNA by 86.9% in the fourth quarter. Millennium Management LLC now owns 1,264,040 shares of the company’s stock valued at $13,652,000 after acquiring an additional 587,668 shares during the period. BlackRock Inc. increased its stake in shares of Codex DNA by 45.2% in the fourth quarter. BlackRock Inc. now owns 484,089 shares of the company’s stock valued at $5,229,000 after buying an additional 150,618 shares in the last quarter. State Street Corp increased its position in Codex DNA by 104.8% in the fourth quarter. State Street Corp now owns 146,710 shares of the company’s stock worth $1,584,000 after purchasing an additional 75,089 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Codex DNA by 421.8% during the 3rd quarter. Geode Capital Management LLC now owns 74,339 shares of the company’s stock valued at $827,000 after purchasing an additional 60,091 shares in the last quarter. Finally, Parametric Portfolio Associates LLC bought a new position in shares of Codex DNA during the 4th quarter valued at about $352,000. Hedge funds and other institutional investors own 87.58% of the company’s stock.

Codex DNA Company Profile (Get Rating)

Codex DNA, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.

Featured Stories

Receive News & Ratings for Codex DNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codex DNA and related companies with's FREE daily email newsletter.